CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
January 30 2008 - 4:01PM
PR Newswire (US)
PALO ALTO, Calif., Jan. 30 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. (NASDAQ:CVTX) today announced that it will
release fourth quarter and year end financial results for 2007
after the market closes on Tuesday, February 26, 2008. Company
management will webcast a conference call at 5:00 p.m. EST, 2:00
p.m. PST, on the company's website. To access the live webcast,
please log on to the Company's website at http://www.cvt.com/ and
go to the Investor Information section. Alternatively, domestic
callers may participate in the conference call by dialing (866)
524-6247, and international callers may participate in the
conference call by dialing (706) 679-3061. Webcast and telephone
replays of the conference call will be available approximately two
hours after the completion of the call through Tuesday, March 4,
2008. Domestic callers can access the replay by dialing (800)
642-1687, and international callers can access the replay by
dialing (706) 645-9291; the PIN access number is 32378484. About CV
Therapeutics CV Therapeutics, Inc., headquartered in Palo Alto,
California, is a biopharmaceutical company focused on applying
molecular cardiology to the discovery, development and
commercialization of novel, small molecule drugs for the treatment
of cardiovascular diseases. CV Therapeutics' approved product,
Ranexa(R) (ranolazine extended-release tablets), is indicated for
the treatment of chronic angina in patients who have not achieved
an adequate response with other antianginal drugs, and should be
used in combination with amlodipine, beta-blockers or nitrates. CV
Therapeutics also has other clinical and preclinical drug
development candidates and programs, including regadenoson, which
is being developed for potential use as a pharmacologic stress
agent in myocardial perfusion imaging studies, and CVT-6883, which
is being developed as a potential treatment for asthma and other
conditions. These product candidates have not been determined by
any regulatory authorities to be safe or effective in humans for
any use. Complete prescribing information for Ranexa, including
detailed safety and dosage information are available at
http://www.ranexa.com/. DATASOURCE: CV Therapeutics, Inc. CONTACT:
John Bluth, Executive Director, Corporate Communications and
Investor Relations of CV Therapeutics, Inc., +1-650-384-8850 Web
site: http://www.cvt.com/ http://www.ranexa.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024